What are the findings of the BASEL study related to the efficacy of brain natriuretic peptide (BNP) assays?

Updated: Jan 08, 2018
  • Author: Donald Schreiber, MD, CM; Chief Editor: Erik D Schraga, MD  more...
  • Print


Swiss investigators examined this hypothesis. In a randomized, controlled study of 452 ED patients with acute dyspnea, Mueller et al found that, although mortality rates were not significantly lowered with BNP measurement, the data suggested that equivalent outcomes can be achieved with lowered hospital and intensive care unit (ICU) admission rates and shortened hospital stays when BNP testing is incorporated into the decision-making process for patient admissions. [8]

In the B-Type Natriuretic Peptide for Acute Shortness of Breath Evaluation (BASEL) study, patients were randomly assigned to undergo standard evaluation or evaluation aided with rapid bedside BNP measurement.

BNP measurement significantly decreased rates of admission (75% vs 85%) and admission to the intensive care unit (ICU) (15% vs 24%). [8] Length of hospitalization was also significantly shortened with BNP measurement, with a median of 8 versus 11 days for the control group. The clinical endpoint of 30-day all-cause mortality occurred in 10% of the BNP group, with 12% mortality in the control group.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!